Document is current

Article History

Received: 10 September 2025

Accepted: 30 September 2025

First Online: 27 October 2025

Declarations

:

: The study is carried out in accordance with the Declaration of Helsinki of the World Medical Association and according to the principles of Good Clinical Practice (GCP) and good scientific practice (GSP). Study participation is voluntary and can be withdrawn at any time. Written informed consent will be obtained prior to participation, if applicable. Patients will be fully informed about aims, procedures, data collection, and the use of collected data in this registry. Refusing participation has no negative consequences for patients. No foreseeable risk results from participating. No compassionate use is carried out. No invasive interventions are conducted. This study is registered at the German Clinical Trials Register (DRKS00027547). Principles of data protection will be upheld. The study has received approval from the local ethics committee (Ethics Board of the Faculty of Medicine at RWTH Aachen University (EK 279/21)). The results of this study will be disseminated via peer-reviewed journals. Deviations from the protocol (e.g. inclusion, recruitment and procedures) will be discussed. This manuscript has been written according to the SPIRIT guidance .

: The contractual partners endeavour to publish the results of their work jointly, and all publications will specify that the results were obtained within the German Dementia Registry.

: KR reports receiving consulting fees from Biogen, Eisai, Lilly and Roche. ASC has received speaker honoraria from Eisai and Lilly and services honoraria from Biogen. AH has received speaker honoraria from Eisai. TO has received speaker honoraria from Lilly, Biogen and Siemens Healthineers. OAO reports receiving consulting fees and speaker honoraria from Biogen, Eisai, Lilly, GE, Synaptikon and Boston Scientific. Outside the submitted work TG reported receiving consulting fees from Acumen, Advantage Ther, Alector, Anavex, Biogen, BMS; Cogthera, Eisai, Eli Lilly, Functional Neuromod., Grifols, Janssen, Neurimmune, Noselab, Novo Nordisk, Roche Diagnostics, and Roche Pharma; lecture fees from Anavex, Cogthera, Eisai, Eli Lilly, FEO, Grifols, Pfizer, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen,Eisai and Eli Lilly. VD has received speaker honoraria from Lilly and sponsorship of scientific events by Eisai, Lilly and Novo Nordisk. JL reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Lilly, BIAL, Merck and Roche, consulting fees from Axon Neuroscience, EISAI, Lilly, Roche and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent “Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies” (PCT/EP2024/053388) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent “Pharmaceutical Composition and Methods of Use” (EP 22 159 408.8) filed by MODAG GmbH. DS receives lecture fees from Lilly and Eisai. FJ has received personal fees for funding and advisory services from the following companies: AC Immune, Biogen, Eisai, GE Healthcare, Grifols, Janssen, Lilly, Novo Nordisk, and Roche. All others report no conflict of interest.